Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesityGeoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.
Persons:
Geoff Meacham, Eli Lilly
Organizations:
Bank of America Securities